文献速递系统性红斑狼疮

系统性红斑狼疮患者恶性肿瘤风险:系统评价与荟萃分析

Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2021-09-30

结果显示总体恶性肿瘤风险轻度升高(RR 1.18,95%CI 1.00-1.38),24种部位特异性恶性肿瘤风险增加,但乳腺癌、子宫癌、黑色素瘤和前列腺癌风险降低。

要点

  • SLE患者总体恶性肿瘤风险轻度升高(RR 1.18,95%CI 1.00-1.38)。
  • 非霍奇金淋巴瘤和霍奇金淋巴瘤风险增加>3倍,骨髓瘤和肝癌>2倍。
  • 乳腺癌、子宫癌、黑色素瘤和前列腺癌风险降低。

核心结论

  • 与一般人群相比,SLE患者总体及部分部位特异性恶性肿瘤风险增加,但部分部位特异性恶性肿瘤风险降低或无差异。

主要发现

  • 汇总分析纳入80 833例患者、3694例事件,所有恶性肿瘤的汇总RR为1.18(95%CI:1.00-1.38)。
  • 24种(62%)部位特异性恶性肿瘤风险在SLE患者中增加。
  • 在≥6项研究的恶性肿瘤中,非霍奇金淋巴瘤和霍奇金淋巴瘤风险增加>3倍,骨髓瘤和肝癌>2倍,宫颈癌、肺癌、膀胱癌和甲状腺癌≥1.5倍,胃癌和脑癌>1.3倍。
  • 乳腺癌、子宫癌、黑色素瘤和前列腺癌四种恶性肿瘤风险降低,另11种恶性肿瘤风险与一般人群无差异。
  • 异质性范围为0%至96%,其中63%不显著。

临床怎么用

  • SLE患者应关注总体及部位特异性恶性肿瘤风险升高,尤其是淋巴瘤、骨髓瘤、肝癌等,同时注意部分癌症风险可能降低。

局限性

  • 异质性范围较宽(0%-96%),部分分析存在显著异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignancy is a potential comorbidity in patients with systemic lupus erythematosus (SLE). However, risk by malignancy type remains to be fully elucidated. We evaluated the risk of malignancy type in SLE patients in a systematic review and meta-analysis. METHODS: MEDLINE and EMBASE were searched from inception to July 2018 to identify observational studies that evaluated malignancy risk in adult SLE patients compared with the general population. Random-effects models were used to calculate pooled risk ratios (RRs) and 95% confidence intervals (CIs). Heterogeneity was quantified using the I2 test. FINDINGS: Forty-one studies reporting on 40 malignancies (one overall, 39 site-specific) were included in the meta-analysis. The pooled RR for all malignancies from 3694 events across 80 833 patients was 1.18 (95% CI: 1.00-1.38). The risk of 24 site-specific malignancies (62%) was increased in SLE patients. For malignancies with ≥6 studies, non-Hodgkin lymphoma and Hodgkin lymphoma risk was increased >3-fold; myeloma and liver >2-fold; cervical, lung, bladder, and thyroid ≥1.5-fold; stomach and brain >1.3-fold. The risk of four malignancies (breast, uterine, melanoma, prostate) was decreased, whereas risk of 11 other malignancies did not differ between SLE patients and the general population. Heterogeneity ranged between 0% and 96%, and 63% were non-significant. INTERPRETATION: The risk of overall and some site-specific malignancies is increased in SLE compared with the general population. However, the risk for some site-specific malignancies is decreased or did not differ. Further examination of risk profiles and SLE patient phenotypes may support guidelines aimed at reducing malignancy risk. FUNDING: AstraZeneca. SYSTEMATIC REVIEW REGISTRATION: PROSPERO number: CRD42018110433.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Clarke AE, Pooley N, Marjenberg Z, et al. Risk of malignancy in patients with systemic lupus erythematosus: Systematic review and meta-analysis. Semin Arthritis Rheum. 2021. PMID: 34710720. doi:10.1016/j.semarthrit.2021.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。